Reducing agents are the other hazard, because reduction of the metal changes its coordination preferences and can release it from the complex, and thiol reagents of the kind routinely present in cell-biology buffers both reduce and chelate
Some committee members said that they worried about the implications of the FDA allowing itself to skip over clinical trials when permitting pharmacies to dispense medications
For injectable or systemic research-compound use, the honest answer is: we do not have long-term human safety data
There is no approved standalone cagrilintide label, so these figures come from clinical trials, not FDA prescribing information
The Hospira label lists the preservative at either 0.9% (9 mg/mL) or 1.1% (11 mg/mL) depending on the presentation, with a pH of 5.7 in a range of 4.5 to 7.0
Peptide Stability and Potential Degradation Pathways